What is Eupraxia Pharmaceuticals Inc.'s (EPRX) StockRank?

MoatMap's StockRank for Eupraxia Pharmaceuticals Inc. (EPRX) is 25/100, with a Sell signal. This is a composite score combining Quality (38), Value (27), and Momentum (48) factor ranks across MoatMap's 20,000+ stock universe.

Does Eupraxia Pharmaceuticals Inc. have an economic moat?

Eupraxia Pharmaceuticals Inc. (EPRX) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Eupraxia Pharmaceuticals Inc. a buy, hold, or sell?

MoatMap's current signal for Eupraxia Pharmaceuticals Inc. (EPRX) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Eupraxia Pharmaceuticals Inc. in?

Eupraxia Pharmaceuticals Inc. (EPRX) operates in the Healthcare sector, specifically the Biotechnology industry (Canada).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

EPRX

SELLREMOVE

Eupraxia Pharmaceuticals Inc. · Healthcare · Canada · $425M · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

-54.5%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Eupraxia is a clinical-stage biotechnology company rather than a validated, high-utilization CDMO, failing our Terry Smith quality filter due to lack of cash flows and high binary clinical risk.

COMPANY DESCRIPTION

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing long-acting, locally delivered, and highly potent pain therapies using its proprietary Diffusphere™ technology. Its competitive moat is this advanced drug delivery technology, designed to provide sustained local therapeutic effect while minimizing systemic exposure, aiming for improved safety and efficacy. Eupraxia is a biotechnology firm innovating in pain management, targeting localized therapies with reduced systemic side effects.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	0	0	0	0	—
EPS	—	-0.32	-0.49	-0.76	-1.03	—
Shares	—	65.3M	65.3M	35.6M	51.9M	-20.5%
Debt	7.3M	9.0M	10.5M	71,859	0.2M	-61.8%
Equity	—	7.8M	2.2M	33.4M	82.0M	119.2%
Op CF	—	-14.4M	-20.7M	-30.0M	-28.6M	—
Inv CF	—	9.8M	-73,377	-75,159	-0.6M	—
Fin CF	—	10.8M	21.1M	45.8M	76.1M	—

PRICE (1Y)-15.1%

SMA 50SMA 200

$6.41

RSI (14)

49.1

52W High

$9.32

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-47.9%15.2

ROE

-54.5%16.1

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-20.4%16.5

Piotroski

321.5

Int. Cover

—N/A

D/E Ratio

0.01x85.8

Current Ratio

19.30x95.2

Value

P/E (TTM)

—N/A

EV/EBITDA

-6.7x25.0

P/FCF

—N/A

P/B

3.7x34.7

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

69%51.8

RS 6M

-16%61.2

SMA 50/200

0.99x62.7

EPS Rev 4W

-4.9%10.0

EPS Rev 12W

-43.9%4.6

EPS Improve

+12%27.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$425M

P/E (Forward)

-7.1x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EPRX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
EPRX	Eupraxia Pharmaceuticals Inc.(you)	$425M	25	SELL
HELP	Cybin D/B/A Helus Pharma	$245M	6	STRONG SELL
OBI.L	Ondine Biomedical Inc.	$101M	20	SELL
NGEN	NervGen Pharma Corp.	$244M	1	STRONG SELL
PMN	ProMIS Neurosciences, Inc.	$97M	15	STRONG SELL
MSLE	Satellos Bioscience Inc.	$119M	10	STRONG SELL
ENGN	enGene Therapeutics Inc.	$114M	8	STRONG SELL
MIST	Milestone Pharmaceuticals Inc.	$161M	1	STRONG SELL
ABCL	AbCellera Biologics Inc.	$1.7B	42	HOLD
EDSA	Edesa Biotech, Inc.	$61M	17	STRONG SELL

Peer medians: ROE -39.7% · P/E 14.3x · Gross margin 35.6%

Eupraxia Pharmaceuticals Inc. (EPRX) — Stock Score Summary

Eupraxia Pharmaceuticals Inc. (EPRX) has a MoatMap StockRank of 25/100 based on Quality (38/100), Value (27/100), and Momentum (48/100) factor scores. The current signal is SELL. Eupraxia is a clinical-stage biotechnology company rather than a validated, high-utilization CDMO, failing our Terry Smith quality filter due to lack of cash flows and high binary clinical risk.

Key Financial Metrics

Price	$6.41
Market Cap	$425M
P/E (Forward)	-7.07
Price/Book	3.74
Return on Equity	-54.5%
Return on Invested Capital	-47.9%
Debt/Equity	1.47
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-18M

Eupraxia Pharmaceuticals Inc. operates in the Biotechnology industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is Eupraxia Pharmaceuticals Inc.’s (EPRX) StockRank?: MoatMap’s StockRank for Eupraxia Pharmaceuticals Inc. (EPRX) is 25/100, with a Sell signal. It is a composite of Quality (38), Value (27), and Momentum (48) factor ranks across MoatMap’s 20,000+ stock universe.
Does Eupraxia Pharmaceuticals Inc. have an economic moat?: Eupraxia Pharmaceuticals Inc. (EPRX) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Eupraxia Pharmaceuticals Inc. a buy, hold, or sell?: MoatMap’s current signal for Eupraxia Pharmaceuticals Inc. (EPRX) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Eupraxia Pharmaceuticals Inc. in?: Eupraxia Pharmaceuticals Inc. (EPRX) operates in the Healthcare sector, specifically the Biotechnology industry (Canada).